BrainStorm Cell Therapeutics Reports 2025 Financial Results and Future Strategy Insights BrainStorm Cell Therapeutics shares its financial performance for 2025, focusing on ALS treatment advancements and corporate developments, alongside attention to regulatory approvals.

BrainStorm Cell Therapeutics Reports 2025 Financial Results and Future Strategy Insights #USA #New_York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Secures $1 Million Strategic Financing Deal with Institutional Partners BrainStorm Cell Therapeutics has announced a strategic $1 million financing deal at a premium, affirming confidence in its neurodegenerative disease therapies.

BrainStorm Cell Therapeutics Secures $1 Million Strategic Financing Deal with Institutional Partners #USA #New_York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Reports Q3 2025 Financial Results and Strategic Developments BrainStorm Cell Therapeutics provides an update on Q3 2025 financial results, key developments for NurOwn, and plans for ALS therapy advancement.

BrainStorm Cell Therapeutics Reports Q3 2025 Financial Results and Strategic Developments #USA #New_York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Reports Strong Q2 2025 Financial Results and Corporate Developments BrainStorm Cell Therapeutics shares its Q2 2025 financial results, highlighting FDA approval for its Phase 3b trial of NurOwn, aimed at ALS treatment.

BrainStorm Cell Therapeutics Reports Strong Q2 2025 Financial Results and Corporate Developments #United_States #New_York #BrainStorm #ALS #NurOwn

Patients Fight for Access to BrainStorm’s ALS Drug After Expanded Access Data ‘Defy Logic’ Participants in trials of BrainStorm Cell Therapeutics' NurOwn filed a Citizens’ Petition with the FDA earlier this month seeking a new review of the stem cell therapy that was rejected in 2022 based ...

Moms filed Citizens Petition asking the #USFDA to approve #NurOwn after it helped their loved ones with ALS "live longer & live better"

www.biospace.com/policy/patie...

#EndALS #patientadvocacy #GoodTrouble #mamabears

#BrainstormCell

BrainStorm Cell Therapeutics Moves from Nasdaq to OTCQB Amid Delisting Notification BrainStorm Cell Therapeutics announces its transition from Nasdaq to OTCQB after receiving a delisting notification, reaffirming dedication to ALS treatments.

BrainStorm Cell Therapeutics Moves from Nasdaq to OTCQB Amid Delisting Notification #USA #New_York #OTCQB #BrainStorm #NurOwn

A New Opportunity for ALS Treatment: NurOwn® Gains Attention from FDA Review BrainStorm Cell Therapeutics welcomes FDA's renewed examination of NurOwn®, a promising treatment for ALS, aiming to solidify its efficacy.

A New Opportunity for ALS Treatment: NurOwn® Gains Attention from FDA Review #United_States #New_York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Releases Promising Survival Data for ALS Patients Treated with NurOwn Therapy Recent findings highlight that 90% of ALS patients treated with BrainStorm's NurOwn survived over five years, challenging typical survival rates.

BrainStorm Cell Therapeutics Releases Promising Survival Data for ALS Patients Treated with NurOwn Therapy #USA #New_York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Partners with Minaris for NurOwn® ALS Trials BrainStorm Cell Therapeutics has announced a significant partnership with Minaris to advance the manufacturing of NurOwn® for ALS clinical trials. Key collaboration details and future plans discussed.

BrainStorm Cell Therapeutics Partners with Minaris for NurOwn® ALS Trials #USA #New_York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Reports Promising Q1 2025 Financial Results and Updates on Pipeline Developments BrainStorm Cell Therapeutics has shared its Q1 2025 financial results along with significant updates regarding its NurOwn therapy for ALS, showcasing promising developments.

BrainStorm Cell Therapeutics Reports Promising Q1 2025 Financial Results and Updates on Pipeline Developments #United_States #New_York #ALS_Treatment #NurOwn #BrainStorm_Cell

Unlocking the Future of ALS Research: BrainStorm's New Insights at the 2025 Summit BrainStorm Cell Therapeutics will share its latest biomarker analysis and trial strategies at the upcoming ALS Drug Development Summit, enhancing ALS research.

Unlocking the Future of ALS Research: BrainStorm's New Insights at the 2025 Summit #United_States #Boston #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Moves Forward with IND Amendment for NurOwn® in ALS Phase 3b Trial BrainStorm Cell Therapeutics has submitted an IND amendment to the FDA for NurOwn®, marking a key step towards a Phase 3b trial for ALS treatment.

BrainStorm Cell Therapeutics Moves Forward with IND Amendment for NurOwn® in ALS Phase 3b Trial #United_States #New_York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Reveals Strong 2024 Financial Outcomes and Future Roadmap BrainStorm Cell Therapeutics Inc. has reported its financial results for the year 2024, showcasing key achievements and future plans in developing therapies for neurodegenerative diseases. The company remains committed to innovation.

BrainStorm Cell Therapeutics Reveals Strong 2024 Financial Outcomes and Future Roadmap #USA #New_York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Receives Nasdaq Compliance Extension Until June 2025 BrainStorm Cell Therapeutics has secured an extension from Nasdaq to meet compliance standards. The company aims to enhance its financial position while advancing its therapies for neurodegenerative diseases.

BrainStorm Cell Therapeutics Receives Nasdaq Compliance Extension Until June 2025 #United_States #New_York #BrainStorm #BCLI #NurOwn

BrainStorm Cell Therapeutics's 2024 Highlights and Future Pathways in ALS Treatment BrainStorm Cell Therapeutics provides an insightful overview of their achievements in 2024 and strategic plans for ALS treatment advancements.

BrainStorm Cell Therapeutics's 2024 Highlights and Future Pathways in ALS Treatment #United_States #New_York #BrainStorm #ALS #NurOwn